Current Studies

Utah Cancer Specialists actively participates in clinical research. This is a list of the studies currently offered at Utah Cancer Specialists. The number following each listing is the control number assigned by the National Cancer Institute. You may search any of these numbers at https://www.clinicaltrials.gov

If you believe one of these studies could be right for you, please consult with your physician. For further information, please contact us at 801 281-6864 or by email at research@utahcancer.com

Studies current as of 3/13/2018:

Breast Cancer Study (3rd Line) #BRE001: For Study Participants with HER2+ Metastatic Breast Cancer who have Received two Prior Treatments.  NCT02492711

Breast Cancer Study #BRE003: For Study Participants with Metastatic Breast Cancer who have Stable Brain Metastases and have been previously treated with Anthracycline, A Taxane, and Capecitabine. NCT02915744

Lung #P1-LNG001: For Study Participants with Non-Small Cell Lung Cancer (NSCLC). NCT02448251

Lymphoma (2nd Line +) #LYM003: For Study Participants with Relapsed Indolent B-Cell Non-Hodgkin’s Lymphoma (iNHL). NCT02367040

Lymphoma #LYM004: For Study Participants with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. NCT01996865

Lymphoma #LYM005: For Study Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. NCT02998476

Solid Tumors/Advanced #P1-STA001: For Study Participants with Advanced Solid Tumors. NCT02880371

Head & Neck #HEN001: For Study Participants with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.  NCT02952586

Melanoma #MEL001:  For Study Participants Previously Untreated with Unresectable or Metastatic BRAF V600 Mutant Melanoma.  NCT02967692

Renal (3rd Line) #REN003:  For Study Participants with Advanced or Metastatic Renal Cell Carcinoma.  NCT03163667